Exploring the Merits of Darbepoetin Utilization in the Elderly: A Boon or a Bane

Cresp®, the world's first biosimilar darbepoetin alfa, offers improved, convenient, and affordable treatment for anemia¹

Maintaining Hb Targets in Elderly CKD Patient

Once-monthly darbepoetin alfa successfully maintained Hb levels within the target range³

Empowering Elderly CKD Patients: The Efficacy of Darbepoetin Alfa

Is Monthly Administration of Darbepoetin Alfa Safe for the Elderly?

Abbreviations: CKD: Chronic kidney disease; Hb: Hemoglobin; SD: Standard deviation.

References: 1. Cresp. Available at: https://www.cresp.in/development.html. Accessed on: 08 January 2024. 2. Alkatheri A, Albekairy A, Al-Rajhi Y, et al. Comparison of the effectiveness of equal doses of short and long-acting erythrocyte stimulating agents for managing anemia in chronic kidney disease adult patients. Int J Med Res Health Sci. 2016;5(12):335–342. 3. Agarwal A, Silver MR, Walczyk M, et al. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. J Am Med Dir Assoc. 2007;8(2):83–90.

LMRC Code: GGI-CO-A1-AQS-DCVN-BANNERS-A24-0191